Last week’s agreement between European Union leadership and President Trump means tariffs on EU pharmaceutical imports could be around 15%. Why it matters: EU countries provide 43% of the active ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," examining the latest scientific ...

BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic ...

BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry ...

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) today released new data on the bioscience industry in the United States. The new report, The U.S ...

Breaking: BIO has released the results of a survey revealing companies’ dependence on Chinese biomanufacturing. Yesterday, a busy day on Capitol Hill featured testimony from a BIO Board member and a ...

BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases. The Court of Appeal decision operates from ...

WASHINGTON, D.C. (January 17, 2025) – The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a list of 15 medicines being ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...

In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.